To resist viral infections, leukocytes perform effector functions, such as direct killing of infected cells (elicited by natural killer cells and T lymphocytes) and production of virusneutralizing antibodies (elicited by B lymphocytes). These effector functions require differentiation of the leukocyte and are preceded by activation of the B-and T-cell receptors and by production of cytokines from multiple cell types. Activation of these effector functions requires a complex signaling network that involves kinases and phosphatases that transfer phosphate groups between each other in the leukocyte cytoplasm. Many viruses have developed systems to resist the effector functions of leukocytes, but (to the best of my knowledge) until now there have been no reports of viral proteins that target these signaling networks. In PNAS, Windheim et al.
(1) report a unique resistance system developed by human adenovirus type . This virus encodes a protein (sec49K) that is secreted from infected cells and targets one of the key regulatory molecules of leukocytes, receptor protein tyrosine phosphatase (RPTP) CD45 (1).
The human adenoviruses (HAdVs, classified in species A-G) were discovered more than 60 years ago and several important scientific advances have been reached while studying these viruses, including the mechanisms of split genes (2, 3), oncogenesis (4) , and modulation of immune responses. The latter mechanisms are mediated by the products of the early region 3 (E3) cassette, which encodes six to nine proteins in a speciesdependent order. Some of these proteins have the capacity to modulate immune responses resulting in persistent infections. During the last three decades, a number of species C HAdV-encoded E3 proteins have been functionally characterized. The E3/19K glycoprotein prevents T-cell recognition of infected cells by preventing transport of class I major histocompatibility complex (MHC) proteins from the endoplasmic reticulum (ER) to the plasma membrane (5), resulting in poor recognition of the infected cell by leukocytes. Down-regulation of class I MHC sensitizes infected cells for degradation by natural killer (NK) cells, but this problem is elegantly subverted by E3/19K, which sequesters (also in the ER) two ligands of the NKGD2 receptor: MHC class I chain-related proteins A and B (MICA and MICB), following that infected cells are killed less efficiently by NK cells (6) . Furthermore, no fewer than four different E3 proteins (E3/6.7K, E3/10.4K, E3/14.5K, and E3/14.7K) inhibit apoptosis of infected cells, an effect that was initially demonstrated by Gooding et al. (7). This effect is achieved mainly by down-regulating plasma membrane receptors involved in TNF-α-mediated apoptosis, including TNF receptor 1 (8), TNF-α-related apoptosis-inducing ligand receptors 1 and 2 (9), and Fas/Apo-1 (10). In addition, inhibition of apoptosis is achieved by modulating the functions of the 14.7K-interacting proteins 1, 2, and 3 (FIP1-3), which are all involved in the TNF-α signaling pathways (11) . In contrast, the E3/ 11.6K protein is overexpressed in the later stages of the life cycle and promotes cell lysis through a mechanism that is not fully understood. However, overexpression of E3/11.6K facilitates escape of progeny virions from the infected cell (12) . Corresponding E3 proteins of HAdVs outside species C are expected to exert similar properties. However, some of the nonspecies C HAdVs also express proteins that are not homologous with the proteins of species C HAdVs. The E3/49K protein is encoded only by species D HAdVs (13) and is larger than any other known HAdV E3 protein. This protein contains multiple N-linked glycans and a few O-linked glycans, a transmembrane domain, and an unusual Ig-fold in the membrane- proximal domain (14) . Unlike other E3 proteins, its expression continues throughout the infection cycle. Initially, the E3/49K protein was localized to the Golgi network and early endosomes and has been suggested to be proteolytically processed.
Here, Windheim et al.
(1) demonstrate unique characteristics of the E3/49K protein and reveal a function that is fundamentally different from the functions previously demonstrated for E3 proteins. First, the authors show that the majority of the ectodomain is actively secreted from infected cells (sek49K) through cleavage by cellular proteases. This process alone is unique because all other HAdV proteins described so far only function within the infected cell. Furthermore, sek49K was demonstrated to bind to multiple types of primary leukocytes and to lymphoid cell lines, but not to epithelial cells or fibroblasts, suggesting an immunomodulatory role of sek49K. Remarkably, sek49 was shown to bind to CD45, a member of the RPTP family that regulates signaling, activity, and differentiation of lymphocytes, including NK cells. Sec49K also inhibited NK cell line-mediated lysis of class I MHC-negative K562 cells. This effect was not seen when sek49K was replaced with cells (Jurkat or A549) that carried noncleavable E3/49K, indicating that the protein must be secreted to exert its immunomodulatory function. In the presence of sek49K, the expression of the activation markers CD25 and CD69 was down-regulated on NK cells and T cells, suggesting that sek49K suppress the activity of these cells. Moreover, purified sec49K suppressed or delayed phosphorylation of the T-cell receptor target protein Zap-70, which is one of the key signaling proteins involved in activation of T cells. Finally, Windheim et al. (1) demonstrate that preincubation of sek49K with peripheral blood mononuclear cells isolated from individuals seropositive for cytomegalovirus (CMV) resulted in a significant decrease of IFN-γ and TNF-α after stimulation with CMV antigens. Taken together, these data demonstrate that sek49K not only interferes with NK cell function but also inhibits T-cell activation and cytokine production.
The present study opens up for several important questions to be addressed: (i) The activity of CD45 appears to be regulated by its dimerization state and its organization in lipid rafts. CD45 belongs to the R1/R6 subgroup of PRTPs that also contain CD148. However, unlike CD45, which is involved in both Band T-cell development/activation and in NK cell function, CD148 is mainly active in signaling and differentiation of B cells. Together with some nonreceptor-type PTPs, these two proteins are key regulators of Srcfamily kinases and other substrates that are important for activation of lymphocytes (15) . To the best of my knowledge, this report of a viral protein that regulates the activity of a member of the RPTP family, which is a large and diverse family of proteins associated with functions beyond immunomodulation, such as in autoimmune diseases, diabetes, cancer, and Parkinson disease (16) , is unique. Obviously, dissection of the immunomodulatory functions of the E3 proteins have contributed to better understanding of adenovirus pathogenicity and persistency, but E3 proteins have also been implicated in prevention of autoimmune diabetes (17) , prolonged duration of transplanted cells (18) , and improved cytotoxicity of cancer cells by oncolytic HAdV-based vectors (19) . Altogether, this suggests that future work in this field has potential to generate novel applications within and beyond the field of viral immunomodulation.
